Home CompanyTechnology Offerings Contact Publications


The current formulation technologies for API powders are lacking in many key characteristics. These include process simplicity, scalability, versatility and cost as well as the performance of the resulting product. Teicos Pharma overcomes these deficiencies via its novel ne-step, continuous powder production technology.

In this process, naturally occuring L-leucine* is self-assembled in a nano-crystalline structure on the surface of the inhalation powder. This coating both reduces the powder adhesion forces and protects the API from the environment.

* L-leucine is one of the essential amino acids which cannot be manufactured in the human body. It aids in the regulation of blood-sugar levels, the growth and repair of muscle tissue, the productions of growth hormone, the healing of wounds as well as energy regulation.


One-step, continuous powder production

Teicos Pharma Ltd
Heinasuontie 29
00430 Helsinki

Home Company Technology Offerings Contact Publications